This Day On The Street
Continue to site
This account is pending registration confirmation. Please click on the link within the confirmation email previously sent you to complete registration.
Need a new registration confirmation email? Click here

Peregrine Pharmaceuticals Inc (PPHM)

NASDAQ: Health Care

Company Cash Flow
Apr 2015 Apr 2014 Apr 2013 Apr 2012
Cash Flow From Operating Activities
Net Income (Loss) -50.36M -35.36M -29.78M -42.12M
Operating Gains/Losses 2.00K 4.00K 1.70M 2.00K
Extraordinary Gains / Losses 0.00 0.00 0.00 0.00
(Increase) Decrease In Receivables -2.48M 330.00K 691.00K -871.00K
(Increase) Decrease in Inventories -1.82M -1.19M -728.00K 1.67M
(Increase) Decrease In Other Current Assets 0.00 0.00 0.00 0.00
(Decrease) Increase In Payables 3.28M -391.00K -691.00K -601.00K
(Decrease) Increase In Other Current Liabilities 194.00K 995.00K -43.00K 3.88M
(Increase) Decrease In Other Working Capital 7.36M 878.00K 3.31M -1.71M
Other Non-Cash Items 6.70M 6.21M 3.44M 2.77M
Net Cash From Continuing Operations -36.02M -28.25M -20.93M -35.88M
Net Cash From Discontinued Operations 0.00 0.00 0.00 0.00
Cash Provided By Investing Activities
Net Cash From Total Operating Activities -36.02M -28.25M -20.93M -35.88M
Sale of Property, Plant & Equipment 0.00 0.00 0.00 0.00
Cash Used for Investing Activities
Sale of Short-Term Investments 0.00 0.00 0.00 0.00
Purchases of Property, Plant & Equipment -9.05M -755.00K -853.00K -1.55M
Acquisitions 0.00 0.00 0.00 0.00
Purchases of Short-Term Investments 0.00 0.00 0.00 0.00
Other Cash from Investing Activities 598.00K -1.77M 102.00K 383.00K
Cash Provided by Financing Activities
Net Cash From Investing Activities -8.45M -2.52M -751.00K -1.17M
Issuance of Debt 0.00 0.00 14.75M 0.00
Cash Used for Financing Activities
Issuance of Capital Stock 38.34M 73.33M 40.15M 33.41M
Repayment of Long-Term Debt -13.00K -32.00K -15.08M -1.41M
Repurchase of Capital Stock 0.00 0.00 0.00 0.00
Payment of Cash Dividends -3.35M -232.00K 0.00 0.00
Other Financing Charges, Net 0.00 0.00 -975.00K 0.00
Net Cash From Financing Activities 34.98M 73.06M 38.85M 32.01M
Effect of Exchange Rate Changes 0.00 0.00 0.00 0.00
Net Change in Cash & Cash Equivalents -9.49M 42.29M 17.17M -5.04M

Check Out Our Best Services for Investors

Action Alerts PLUS

Portfolio Manager Jim Cramer and Director of Research Jack Mohr reveal their investment tactics while giving advanced notice before every trade.

Product Features:
  • $2.5+ million portfolio
  • Large-cap and dividend focus
  • Intraday trade alerts from Cramer
Quant Ratings

Access the tool that DOMINATES the Russell 2000 and the S&P 500.

Product Features:
  • Buy, hold, or sell recommendations for over 4,300 stocks
  • Unlimited research reports on your favorite stocks
  • A custom stock screener
Stocks Under $10

David Peltier uncovers low dollar stocks with serious upside potential that are flying under Wall Street's radar.

Product Features:
  • Model portfolio
  • Stocks trading below $10
  • Intraday trade alerts
14-Days Free
Only $9.95
14-Days Free
Dividend Stock Advisor

David Peltier identifies the best of breed dividend stocks that will pay a reliable AND significant income stream.

Product Features:
  • Diversified model portfolio of dividend stocks
  • Updates with exact steps to take - BUY, HOLD, SELL
Trifecta Stocks

Every recommendation goes through 3 layers of intense scrutiny—quantitative, fundamental and technical analysis—to maximize profit potential and minimize risk.

Product Features:
  • Model Portfolio
  • Intra Day Trade alerts
  • Access to Quant Ratings
Real Money

More than 30 investing pros with skin in the game give you actionable insight and investment ideas.

Product Features:
  • Access to Jim Cramer's daily blog
  • Intraday commentary and news
  • Real-time trading forums
Only $49.95
14-Days Free
14-Days Free

PPHM Peregrine Pharmaceuticals Inc

Chart of PPHM

Analysts Ratings for PPHM

Rating Current 1-Mo Ago 2-Mo Ago 3-Mo Ago
Strong Buy 4 3 3 3
Moderate Buy 0 0 0 0
Hold 0 0 0 0
Moderate Sell 0 0 0 0
Strong Sell 0 0 0 0

PPHM Chatter

Top Rated Stocks Top Rated Funds Top Rated ETFs